niraparib
niraparib: 26 clinical trials tracked.
niraparib evidence translation
What we can confirm
26 tracked trials
What it means
What to watch
Prepared research question
What is verified about niraparib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 10 study sponsors
Related indications
Clinical Trials (26)showing 10 most recent
A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Primary endpoint: Overall Survival
ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy
Primary endpoint: Progression-free survival (PFS) in the experimental arm
An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)
Primary endpoint: Part A and Part B: Confirmed Objective Response (OR) According to RECIST v1.1 as Assessed by Investigator
Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Primary endpoint: Progression-free survival (PFS)
SOPRANO: Stereotactic Radiotherapy Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARP Inhibitor Therapy
Primary endpoint: Progression free survival
An Open-label, Single-arm, Phase II Study to Investigate the Efficacy and Safety of Niraparib Combined With Anlotinib Maintenance Retreatment in PSR Ovarian Cancer Patients, Who Have Previously Received PARPi Maintenance Treatment.
Primary endpoint: Progression free survival (PFS)
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer
Primary endpoint: To investigate the safety and tolerability of ZN-c3 in combination with niraparib, including identification of the MTD and RP2D
An Open-Label, Single Arm, Phase II Trial of Niraparib in Combination With Anlotinib in Patients With Platinum-Resistant Recurrent or Platinum-Refractory Clear Cell Ovarian Cancer.
Primary endpoint: Objective response rate
Zedula Special Drug Use Observational Study "Ovarian Cancer"
Primary endpoint: Number of Participants with Adverse Event of Myelosuppression
Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate Cancer
Primary endpoint: Composite radiographic progression-free survival(rPFS) and biochemical (PSA) progression-free survival (PFS)